CRMD - שווי שוק לנפח מכירות CorMedix Inc

Recurring Defencath sales in dialysis centers provide CorMedix Inc. (CRMD) with a steady stream of free cash flow. Business flexibility is maintained by outsourcing production and research to external contractors. The company's P/S ratio dynamics clearly confirm the current valuation, where 0.80 records a new level. This approach renders the asset defensive, as demand for medical innovation remains independent of macroeconomic crises.

The P/S multiple determines the market value of a business relative to its annual revenue, allowing an investor to assess the premium paid per unit of generated income. The price-to-sales ratio trend reflects market expectations for the expansion of CorMedix Inc. (CRMD), whose strong pricing power in the infection prevention segment and lack of competitors justify the potential for capitalization growth as sales scale.